RecruitingPhase 2NCT06477653
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Studying Hypereosinophilic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Amy D Klion, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- dupilumab(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06477653 on ClinicalTrials.govOther trials for Hypereosinophilic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07275190The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic SyndromeFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE3NCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE3NCT04191304A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)AstraZeneca
- RECRUITINGNCT04538937Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing EosinophilsMedical University Innsbruck
- RECRUITINGPHASE2NCT03801434Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic DisordersWilliam Shomali
- RECRUITINGNCT04018118Natural History of Hypereosinophilia and Hypereosinophilic SyndromesUniversity Hospital, Lille
- RECRUITINGNCT00091871A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE2NCT00044304Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeNational Institute of Allergy and Infectious Diseases (NIAID)